

Video Transcript: “Clinical Trial Tests Nivolumab for Patients with Rare Brain and Spine Cancers” (Audio Described)

[Soft, upbeat music]

Audio Description: Outdoor sign that reads: “Clinical Center, Building 10, South Entrance.”

A clinical trial title appears as text across the screen: “Phase 2 clinical trial. Immune Checkpoint Inhibitor Nivolumab for Patients with Rare CNS Cancers.”

Marta Penas-Prado, M.D., NCI-CONNECT senior clinician, sits in her office.

Marta Penas-Prado: This is a trial using nivolumab, which is an immunotherapy drug, to treat patients with rare brain and spine tumors.

Audio Description: Animation of immune cells attacking a tumor.

Penas-Prado: So what we are trying to achieve is to wake up the immune system in a way that it can recognize the tumor cells and fight against the tumor and stop its growth.

Audio Description: Dr. Penas-Prado speaking to a patient in clinic.

Penas-Prado: So we preliminarily evaluated a group of patients treated in this study, and we realized that their tumor was controlled for a much longer time than what we had expected.

Audio Description: A brain MRI scan showing a tumor, followed by Dr. Penas-Prado speaking in her office.

Penas-Prado: People are eligible if they have a tumor of the brain or the spine—or in both places—that is considered rare. And if the tumor has returned after prior treatment, they are potentially eligible to participate.

Audio Description: An aerial view of the NIH Clinical Center, followed by a close up of an IV drip.

Penas-Prado: The treatment is given here at the Clinical Center at the National Institutes of Health in Bethesda, Maryland. And it’s given as an IV infusion into the vein.

Audio Description: Footage of the NIH Clinical Center atrium, followed by Dr. Penas-Prado speaking in her office.

Penas-Prado: There are also two other centers in the United States participating with us. One is MD Anderson in Houston and the other is Northwestern in Chicago.

Audio Description: Dr. Penas-Prado in the clinic with a patient. She points at a computer screen showing statistics about medulloblastoma.

Penas-Prado: My hope is that this study will offer a treatment option for people who otherwise rarely have any access to clinical trials and very few standard treatments that work.

Audio Description: Animation showing a close-up of immune cells attacking a tumor, followed by another shot of Dr. Penas-Prado speaking in her office.

Penas-Prado: I also hope that it will help us tremendously to understand how the immune system and these rare tumors interact so we can develop better therapies for them in the future.

Audio Description: Text on the screen showing the NCI-CONNECT website URL: cancer.gov/nci-connect.

To request a consultation, your primary doctor should call: (240) 760-6010

NIH National Cancer Institute logo.